Business Context and Reporting Period
This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders held by vTv Therapeutics Inc. on June 11, 2024. The company is incorporated in Delaware and its Class A common stock trades on the NASDAQ Capital Market under the symbol VTVT.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Election of Directors: Stockholders elected seven nominees to the Board of Directors for terms expiring at the 2025 annual meeting. All nominees received significant "For" votes, with "Broker Non-Votes" totaling 294,269 for each candidate.
- Equity Incentive Plan: Stockholders approved the adoption of the 2024 Equity Incentive Plan. The vote was 1,814,842 For, 103,928 Against, and 1,925 Abstain.
- Ratification of Auditors: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The vote was 2,106,193 For, 9,580 Against, and 99,191 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Confirmation that the 2024 Equity Incentive Plan was successfully adopted by stockholders.
- Verification of the re-election of the current Board of Directors, including Fahed Al Marzooqi, who received the highest number of "Withheld" votes (33,597) among the nominees.
- Confirmation that Ernst & Young LLP remains the independent auditor for the 2024 fiscal year.
- Review of the total number of shares represented at the meeting, indicated by the sum of votes cast and broker non-votes.